HYFT MindWalk Holdings Corp. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1715925 · Reporting currency CAD · Fiscal year ends 04/30
Financial factors as of 2026-01-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY28.5%
TTM net income YoY73.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin60.3%
Operating margin—
Net margin-66.5%
FCF margin-64.8%
EBITDA margin—
Returns
ROE-61.5%
ROA-35.7%
ROIC (approx.)—
Asset turnover0.54x
Leverage & solvency
Liabilities / assets35.4%
Debt / equity0.00x
Current ratio3.74x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-3.1%
Payout ratio—
Capex / revenue4.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-04-30 | FY2024*2024-04-30 | FY2023*2023-04-30 | FY2022*2022-04-30 | FY2021*2021-04-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 24.52M | 24.52M | 20.66M | 19.36M | 17.91M |
| Cost of revenue | 10.97M | 12.46M | 9.10M | 8.38M | 6.37M |
| Gross profit | 13.55M | 12.05M | 11.56M | 10.98M | 11.54M |
| R&D expense | 4.94M | 4.04M | 14.10M | 7.66M | 1.97M |
| SG&A expense | 14.73M | 15.59M | 15.38M | 15.38M | 1.44M |
| Interest expense | 199,000 | 402,000 | 746,000 | 979,000 | 804,000 |
| Pretax income | -34.27M | -28.70M | -27.75M | -15.85M | -6.00M |
| Income tax | -4.03M | -2.59M | -1.19M | 861,000 | 1.34M |
| Net income | -30.23M | -26.11M | -26.56M | -16.71M | -7.34M |
| EPS (basic) | -0.91 | -1.02 | -1.07 | -0.85 | -0.45 |
| EPS (diluted) | -0.91 | -1.02 | -1.07 | -0.85 | -0.45 |
| Balance sheet | |||||
| Cash & equivalents | 10.79M | 3.54M | 8.37M | 30.05M | 41.84M |
| Inventory | 2.10M | 2.14M | 2.06M | 1.61M | 1.20M |
| Current assets | 18.75M | 11.49M | 16.79M | 37.47M | 48.86M |
| PP&E, netmay include right-of-use assets (IFRS) | 15.76M | 16.70M | 10.39M | 10.39M | 4.02M |
| Goodwill | 8.23M | 7.69M | 19.17M | 19.64M | 7.78M |
| Intangibles | 1.07M | 23.56M | 30.93M | 32.39M | 6.06M |
| Total assets | 44.44M | 59.99M | 77.81M | 93.65M | 66.96M |
| Current liabilities | 9.01M | 8.12M | 5.92M | 9.29M | 6.07M |
| Total liabilities | 20.82M | 24.31M | 20.01M | 18.36M | 10.04M |
| Shareholders' equity | 23.63M | 35.68M | 58.51M | 75.28M | 56.92M |
| Shares outstanding | 46.15M | 26.94M | 25.05M | 24.48M | 19.17M |
| Cash flow statement | |||||
| Operating cash flow | -6.41M | -3.18M | -19.83M | -9.92M | -600,000 |
| Capital expenditure | 799,000 | 1.40M | 1.50M | 1.07M | 1.38M |
| Free cash flow | -7.21M | -4.58M | -21.33M | -10.99M | -1.98M |
| Investing cash flow | -799,000 | -1.56M | -1.97M | -5.21M | -2.46M |
| Financing cash flow | 14.89M | 1.02M | -621,000 | 2.88M | 43.38M |
| Depreciation & amortization | 5.12M | 5.74M | 6.68M | 3.77M | 2.74M |
| Stock-based compensation | 445,000 | 1.53M | 1.94M | 3.08M | 2.75M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.